Literature DB >> 11699032

S-100b and neuron-specific enolase in patients with fulminant hepatic failure.

G I Strauss1, M Christiansen, K Møller, J O Clemmesen, F S Larsen, G M Knudsen.   

Abstract

Patients with fulminant hepatic failure (FHF) frequently develop cerebral edema and intracranial hypertension. The aim of this study was to evaluate circulating S-100b and neuron-specific enolase (NSE) levels as markers of neurological outcome in patients with FHF. In a subgroup of patients, the cerebral flux of S-100b and NSE was measured. We included 35 patients with FHF, 6 patients with acute on chronic liver disease (AOCLD), 13 patients with cirrhosis of the liver without hepatic encephalopathy, and 8 healthy subjects. Blood samples were obtained from catheters placed in the radial artery and internal jugular bulb. The net cerebral flux of S-100b and NSE was measured, and the effect of short-term hyperventilation, as well as the effect of high-volume plasmapheresis, on circulating levels of these two biomarkers was determined. Blood levels of S-100b were greater in patients with FHF and AOCLD than patients with cirrhosis and healthy subjects (median, 0.39 microg/L; range, 0.02 to 10.31 microg/L; and 1.11 microg/L; range, 0.19 to 4.84 microg/L v 0.05 microg/L; range, 0.02 to 0.27 microg/L; and 0.09 microg/L; range, 0.02 to 0.15 microg/L, respectively; P <.05, ANOVA). Among patients with FHF, blood levels of NSE tended to be greater in patients who subsequently developed cerebral herniation than in survivors (median, 10.5 microg/L; range, 5.2 to 15.9 microg/L v 5.1 microg/L; range, 2.8 to 12 microg/L; P =.05). There was no net cerebral flux of S-100b or NSE. Short-term hyperventilation had no effect on any of these measures, whereas high-volume plasmapheresis reduced circulating S-100b levels from 0.45 microg/L (range, 0.19 to 10.31 microg/L) to 0.42 microg/L (range, 0.11 to 6.35 microg/L; P =.01). In conclusion, blood levels of S-100b were elevated in almost all patients with FHF and AOCLD, but were unrelated to survival. Conversely, NSE showed a clear tendency toward greater circulating levels in patients with FHF who subsequently developed cerebral herniation than in survivors. This finding encourages further evaluation of NSE as a marker of neurological outcome in FHF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11699032     DOI: 10.1053/jlts.2001.28742

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  10 in total

Review 1.  Therapy of intracranial hypertension in patients with fulminant hepatic failure.

Authors:  Murugan Raghavan; Paul E Marik
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

2.  Clinical scenarios for the use of S100β as a marker of hepatic encephalopathy.

Authors:  Andrés Duarte-Rojo; Astrid Ruiz-Margáin; Ricardo U Macias-Rodriguez; Francisco Javier Cubero; José Estradas-Trujillo; Rosa Ma Muñoz-Fuentes; Aldo Torre
Journal:  World J Gastroenterol       Date:  2016-05-07       Impact factor: 5.742

3.  Role of Brain Biomarkers S-100-Beta and Neuron-Specific Enolase for Detection and Follow-Up of Hepatic Encephalopathy in Cirrhosis before, during and after Treatment with L-Ornithine-L-Aspartate.

Authors:  Hendrik Strebel; Bernhard Haller; Maximilian Sohn; Wolfgang Schepp; Felix Gundling
Journal:  GE Port J Gastroenterol       Date:  2020-04-21

4.  Hepatic Encephalopathy in Children With Acute Liver Failure: Utility of Serum Neuromarkers.

Authors:  Nicole A Toney; Michael J Bell; Steven H Belle; Regina M Hardison; Norberto Rodriguez-Baez; Kathleen M Loomes; Yoram Vodovotz; Ruben Zamora; Robert H Squires
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-07       Impact factor: 2.839

Review 5.  Acute liver failure.

Authors:  Ludwig Kramer
Journal:  Wien Klin Wochenschr       Date:  2004-02-16       Impact factor: 1.704

6.  Novel spheroid reservoir bioartificial liver improves survival of nonhuman primates in a toxin-induced model of acute liver failure.

Authors:  Yi Li; Qiong Wu; Yujia Wang; Chengxin Weng; Yuting He; Mengyu Gao; Guang Yang; Li Li; Fei Chen; Yujun Shi; Bruce P Amiot; Scott L Nyberg; Ji Bao; Hong Bu
Journal:  Theranostics       Date:  2018-11-09       Impact factor: 11.556

Review 7.  The Immune Pathogenesis of Acute-On-Chronic Liver Failure and the Danger Hypothesis.

Authors:  Rui Qiang; Xing-Zi Liu; Jun-Chi Xu
Journal:  Front Immunol       Date:  2022-07-14       Impact factor: 8.786

Review 8.  Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis.

Authors:  Donna M Wilcock; W Sue T Griffin
Journal:  J Neuroinflammation       Date:  2013-07-16       Impact factor: 8.322

9.  Decreased S100B expression in chronic liver diseases.

Authors:  Su Jung Baik; Tae Hun Kim; Kwon Yoo; Il Hwan Moon; Ju Young Choi; Kyu Won Chung; Dong Eun Song
Journal:  Korean J Intern Med       Date:  2016-06-03       Impact factor: 2.884

10.  The association between FABP7 serum levels with survival and neurological complications in acetaminophen-induced acute liver failure: a nested case-control study.

Authors:  Constantine J Karvellas; Jaime L Speiser; Mélanie Tremblay; William M Lee; Christopher F Rose
Journal:  Ann Intensive Care       Date:  2017-10-05       Impact factor: 6.925

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.